Abstract |
Two contrasting cases of chronic refractory pure red cell aplasia (PRCA) responsive to a commercial preparation of horse antihuman thymocyte globulin (ATG) are reported. Both cases were refractory to trials of cyclophosphamide, corticosteroids, and plasmapheresis. One patient developed a reticulocytosis after a single intravenous infusion of ATG; the other patient responded after administration of 14.7 g of ATG over a 28-day course. At presentation, erythroid progenitors (CFU-E and BFU-E) in one patient were normal; in the second patient, the number of erythroid progenitors was severely reduced. Neither patient had a serum IgG inhibitor to progenitor cells as judged by in vitro erythroid colony studies. Both patients had increased numbers of marrow T-cells and co-culture studies in one case were consistent with T-cell-mediated suppression of erythropoiesis. These studies confirm that ATG is a useful agent in the treatment of refractory PRCA. However, ATG may not act by removal of T suppressor cells in all cases.
|
Authors | K F Mangan, R K Shadduck |
Journal | American journal of hematology
(Am J Hematol)
Vol. 17
Issue 4
Pg. 417-26
( 1984)
ISSN: 0361-8609 [Print] United States |
PMID | 6238526
(Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Adult
- Anemia, Aplastic
(immunology, therapy)
- Antilymphocyte Serum
(therapeutic use)
- Bone Marrow
(pathology)
- Chronic Disease
- Colony-Forming Units Assay
- Erythrocytes
(pathology)
- Erythropoiesis
- Female
- Humans
- Middle Aged
- Phenotype
- T-Lymphocytes
(immunology)
- T-Lymphocytes, Regulatory
(immunology)
|